x
OncoIndx® is a next-generation sequencing (NGS) test designed to support treatment planning for patients with complex, advanced, or treatment-resistant solid tumors. With over 1,000 genes, deep sequencing, and AI-powered reporting, OncoIndx® offers a powerful foundation for personalized oncology, enabling therapeutic decision-making across the entire cancer care journey.
With the ability to process both tissue and blood (liquid biopsy) samples, the test makes it easier to evaluate patients even when invasive sampling is not possible.
Proprietary 1,000+ gene panel targeting all major solid tumors
Compatible with both tissue (FFPE) and liquid biopsy (cfDNA)
Enables therapy selection, resistance analysis, and trial matching
Integrated AI reporting via iCare™ platform
High-depth sequencing: 2000x (tissue) / 10000x (liquid)
Includes markers for TMB, MSI, HRD, CNVs, fusions, and pharmacogenomics
Covers SNVs, INDELs, CNVs, gene fusions, TMB, MSI, HRD scoring, and pharmacogenomics.
Uses either blood (cfDNA) or FFPE tissue, expanding accessibility and reducing procedural delays.
The iCare™ analysis platform delivers real-time reports with integrated clinical evidence and therapy suggestions, including ongoing trial relevance.
Outputs include mutation-level details, LOH, TAI, LST for HRD, and immunotherapy readiness (PD-L1 via IHC or CTCs).
Guide advanced and refractory cases with therapeutic insight
Stratify patients for targeted therapy, immunotherapy, or trial enrollment
Detect resistance or progression mechanisms after therapy
Support biomarker discovery and pan-cancer profiling
Enable genomic analysis for patient selection in clinical trials
Clinical-Grade Panel: Over 1,000 genes and 138 fusion partners
Validated Accuracy: SNVs, CNVs, fusions, and indels with >95% concordance
Real-World Utility: Designed for high-need cases where genomic insight can drive meaningful intervention
Traceability to Clinical Trials: Data aligned with global trial matching tools
Pharmacogenomics Support: Includes 36 key markers for drug response prediction
| Tissue | Liquid Biopsy® | |
|---|---|---|
| Sample Type | FFPE block (20–30% tumor content) | Plasma cfDNA + optional whole blood |
| Volume | 1 FFPE block | 8.5 mL (PAXgene or EDTA tube) |
| DNA Input | >1 ng | >1 ng |
| Sequencing Platform | Illumina | Illumina |
| Read Length | 2×150 bp | 2×150 bp |
| Depth | 2000x | 10000x |
| Turnaround Time | 10–14 Days | 10–14 Days |
| Analysis & Reporting | iCare™ AI platform | iCare™ AI platform |
A Comprehensive Genome Profiling Assay for Pan-Cancer Investigations
| Alteration | *PPV | *NPV | Accuracy | Specificity | Sensitivity |
|---|---|---|---|---|---|
| SNVs | 100 | 100 | 100 | 100 | 100 |
| Small INDELs | 100 | 94.03 | 97.40 | 100 | 95.60 |
| CNA | 100 | 100 | 100 | 100 | 100 |
| Fusions | 100 | 96.43 | 98.48 | 100 | 97.44 |
*NPV: Negative predictive value. PPV: Positive predictive value.
EGFR, ALK, KRAS, BRAF, ROST, RET, MET, ERBB2, NTRK1/2/3
BRCA1/2, HER2, PIK3CA, MLH1, MSH6, PMS2
KRAS, NRAS, BRAF, TP53, MLH1, MSH2, SMAD4
BRCA1/2, ATM, CDK12, AR
KRAS, BRAF, PDGFRA, KIT, MET
BRCA1/2, PALB2, TP53, MLH1, MSH2
FGFR2/3, TP53, NTRK1/2/3
BRAF, RET, NRAS, TERT